NeuBase Therapeutics IncNASDAQ:NBSENASDAQ FSI:H. Deficient and Delinquent (Issuer failed to meet continued listing requirements and missed regulatory filing deadline)
- LAST PRICE0.4200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.3950/ 465
- Ask / Lots0.4766/ 10
- Open / Previous Close0.0000 / 0.4200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NBSE |
|---|---|---|
| 09:32 ET | 916 | 0.4163 |
| 09:36 ET | 3109 | 0.401 |
| 09:38 ET | 150 | 0.401 |
| 09:39 ET | 15821 | 0.40545 |
| 09:59 ET | 1850 | 0.4199 |
| 10:26 ET | 100 | 0.41 |
| 10:32 ET | 9998 | 0.411 |
| 10:46 ET | 2700 | 0.4111 |
| 11:04 ET | 100 | 0.4155 |
| 11:18 ET | 200 | 0.4111 |
| 11:26 ET | 1931 | 0.42 |
| 11:40 ET | 16750 | 0.411 |
| 11:42 ET | 16433 | 0.401032 |
| 11:44 ET | 1096 | 0.4011 |
| 11:49 ET | 7100 | 0.41 |
| 12:03 ET | 100 | 0.4011 |
| 12:05 ET | 100 | 0.4016 |
| 12:09 ET | 100 | 0.4016 |
| 12:21 ET | 6314 | 0.4111 |
| 12:27 ET | 6200 | 0.4061 |
| 12:30 ET | 9100 | 0.4011 |
| 12:32 ET | 12684 | 0.4011 |
| 12:34 ET | 6000 | 0.4012 |
| 12:41 ET | 500 | 0.4012 |
| 01:03 ET | 100 | 0.4017 |
| 01:10 ET | 200 | 0.4013 |
| 01:33 ET | 19998 | 0.4012 |
| 01:55 ET | 10306 | 0.4107 |
| 01:57 ET | 3019 | 0.4035 |
| 03:45 ET | 500 | 0.41 |
| 03:50 ET | 495 | 0.41 |
| 03:56 ET | 100 | 0.4199 |
| 03:57 ET | 377 | 0.42 |
Apr 5, 2024
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq, from 4:05PM ET on Friday Apr 05, 2024 by Dow Jones
4:05PM ET on Friday Apr 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NeuBase Therapeutics Inc | 1.6M | -0.1x | --- |
Company Information
NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.
Contact Information
- Headquarters
- 350 Technology DrivePITTSBURGH, PA, United States 15219
- Phone
- 412-763-3350
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Dov Goldstein
- Interim Chief Executive Officer, Chief Financial Officer
- Todd Branning
- Director
- Dietrich Stephan
- Independent Director
- Gerald McDougall
- Independent Director
- Franklyn Prendergast
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-7.78 |
Book Value | $10.99 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
